Dedifferentiated Liposarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Orphanet: ⁵⁸ Dedifferentiated liposarcoma (DDLS) is a high-grade subtype of liposarcoma (LS; see this term) that progresses from well-differentiated liposarcoma (WDLS; see this term), and most often occurs in the retroperitoneum. It is defined as a region of nonlipogenic sarcoma associated with WDLS. .

MalaCards based summary: Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to liposarcoma and pleomorphic liposarcoma. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are Cellular Senescence and Endometrial cancer. The drugs Doxorubicin and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include lymph node, bone and colon, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology: ¹¹ A liposarcoma that is characterized as a high-grade tumor that occurs when a lower-grade tumor changes and creates new high-grade cells.

Sources

Related Diseases for Dedifferentiated Liposarcoma

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)

#	Related Disease	Score	Top Affiliating Genes
1	liposarcoma	32.1	TP53 RB1 PPARG MDM2 HMGA2 EWSR1
2	pleomorphic liposarcoma	32.0	TP53 SSX2 SS18 SERPINA3 MDM2 KIT
3	well-differentiated liposarcoma	31.5	TP53 SSX2 SS18 SERPINA3 MDM2 KIT
4	cutaneous fibrous histiocytoma	31.5	SERPINA3 S100B F13A1 DES CD34 ACTC1
5	fibrous histiocytoma	31.4	SERPINA3 S100B F13A1 EWSR1 DES CD34
6	lipomatosis, multiple	31.4	TP53 SERPINA3 MDM2 KIT HMGA2 EWSR1
7	osteogenic sarcoma	31.3	TP53 RB1 MIR199A1 MDM2 CDK4
8	fibrosarcoma	31.3	TP53 KIT EWSR1 DES ACTC1
9	malignant fibrous histiocytoma	31.2	TP53 SERPINA3 S100B MDM2 KIT F13A1
10	sarcoma	31.2	TP53 SSX2 SS18 SERPINA3 S100B RB1
11	retroperitoneal sarcoma	31.0	MDM2 KIT HMGA2 CDK4 CD34
12	leiomyosarcoma	31.0	TP53 SERPINA3 S100B RB1 MDM2 KIT
13	inflammatory myofibroblastic tumor	30.9	TP53 SSX2 SS18 MDM2 KIT EWSR1
14	mesenchymal cell neoplasm	30.9	TP53 SSX2 SS18 SERPINA3 MIR199A1 MDM2
15	spindle cell liposarcoma	30.9	MDM2 CDK4 CD34
16	sclerosing liposarcoma	30.9	MDM2 KIT CD34
17	retinoblastoma	30.9	TP53 RB1 PPARG MDM2 CDK4
18	colonic benign neoplasm	30.9	TP53 SERPINA3 PPARG MIR199A1
19	malignant peripheral nerve sheath tumor	30.8	TP53 S100B MDM2 KIT CDK4 CD34
20	desmoid tumor	30.8	TP53 MDM2 KIT DES CD34 ACTC1
21	rhabdomyosarcoma	30.8	TP53 SSX2 S100B RB1 MDM2 KIT
22	malignant inflammatory fibrous histiocytoma	30.8	SERPINA3 MDM2 CDK4 CD34
23	fasciitis	30.8	TP53 DES CD34 ACTC1
24	myxofibrosarcoma	30.8	TP53 SSX2 SS18 SERPINA3 MDM2 KIT
25	malignant mesenchymoma	30.8	SSX2 SERPINA3 MDM2 CD34
26	mixed liposarcoma	30.8	TP53 MDM2 KIT CDK4 CD34
27	sarcomatosis	30.8	KIT EWSR1
28	mediastinum liposarcoma	30.7	MDM2 CDK4
29	spindle cell sarcoma	30.7	TP53 SSX2 SS18 SERPINA3 S100B MDM2
30	inflammatory liposarcoma	30.7	MDM2 CDK4 CD34
31	myxoid liposarcoma	30.7	TP53 SSX2 SS18 MDM2 KIT HMGA2
32	bone sarcoma	30.6	TP53 SERPINA3 MIR199A1 MDM2 EWSR1 CDK4
33	infiltrating lipoma	30.6	MDM2 HMGA2 CDK4 CD34
34	retroperitoneal leiomyosarcoma	30.6	KIT CD34
35	extraosseous osteosarcoma	30.6	MDM2 KIT CDK4 CD34
36	uterus leiomyosarcoma	30.6	KIT HMGA2 DES ACTC1
37	connective tissue benign neoplasm	30.6	TP53 SERPINA3 MDM2 KIT EWSR1 CDK4
38	angiomyolipoma	30.6	TP53 KIT DES ACTC1
39	breast malignant phyllodes tumor	30.6	TP53 SERPINA3 KIT CD34
40	li-fraumeni syndrome	30.6	TP53 RB1 MDM2 CDK4
41	meningioma, familial	30.5	TP53 SERPINA3 S100B MDM2 KIT EWSR1
42	pseudosarcomatous fibromatosis	30.5	SS18 SERPINA3 KIT EWSR1 DES CD34
43	myoma	30.5	TP53 KIT HMGA2 CD34 ACTC1
44	melanoma, cutaneous malignant 1	30.5	TP53 RB1 MDM2 KIT CDK4
45	spindle cell lipoma	30.5	MDM2 HMGA2 DDIT3 CDK4 CD34
46	heart cancer	30.5	SS18 SERPINA3 MDM2 KIT CD34
47	vascular cancer	30.5	TP53 SERPINA3 KIT EWSR1 CD34
48	small cell cancer of the lung	30.4	TP53 RB1 KIT
49	neurilemmoma	30.4	SERPINA3 S100B KIT DES CD34 ACTC1
50	epithelioid sarcoma	30.4	SSX2 SS18 SERPINA3 EWSR1 CD34

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:

Sources

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

GenomeRNAi Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	CD34 CDK4 DDIT3 DES F13A1 MDM2

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.34	ACTC1 CD34 CDK4 DDIT3 DES EWSR1
2	neoplasm	MP:0002006	10.21	CD34 CDK4 DDIT3 EWSR1 HMGA2 KIT
3	normal	MP:0002873	10.19	ACTC1 CDK4 EWSR1 KIT MDM2 MIR193B
4	cellular	MP:0005384	10.15	ACTC1 CD34 CDK4 DDIT3 DES EWSR1
5	endocrine/exocrine gland	MP:0005379	10.14	CDK4 DDIT3 EWSR1 F13A1 HMGA2 KIT
6	muscle	MP:0005369	10.11	ACTC1 CDK4 DES EWSR1 KIT MDM2
7	behavior/neurological	MP:0005386	10.1	ACTC1 CDK4 DDIT3 DES EWSR1 F13A1
8	renal/urinary system	MP:0005367	10.08	CDK4 EWSR1 HMGA2 KIT MDM2 PPARG
9	cardiovascular system	MP:0005385	10.06	ACTC1 CDK4 DDIT3 DES F13A1 KIT
10	reproductive system	MP:0005389	9.85	CDK4 EWSR1 F13A1 HMGA2 KIT MDM2
11	hematopoietic system	MP:0005397	9.73	ACTC1 CD34 CDK4 DDIT3 EWSR1 F13A1
12	integument	MP:0010771	9.44	CD34 CDK4 EWSR1 F13A1 HMGA2 KIT

Sources

Drugs & Therapeutics for Dedifferentiated Liposarcoma

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

2

Anti-Bacterial Agents

Phase 2, Phase 3

3

Antibiotics, Antitubercular

Phase 2, Phase 3

4

Liposomal doxorubicin

Phase 2, Phase 3

5

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

6

Ifosfamide

Approved

Phase 2

3778-73-2

3690

7

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

8

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

9

Nivolumab

Approved

Phase 2

946414-94-4

10

Ipilimumab

Approved

Phase 2

477202-00-9

11

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

12

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

13

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

14

Pioglitazone

Approved, Investigational

Phase 2

111025-46-8

4829

15

Palifosfamide

Investigational

Phase 2

31645-39-3

100427

16

Immunoglobulins, Intravenous

Phase 2

17

Immunoglobulin G

Phase 2

18

Protein Kinase Inhibitors

Phase 2

19

Immunoglobulins

Phase 2

20

Antibodies, Monoclonal

Phase 2

21

Antibodies

Phase 2

22

Antineoplastic Agents, Immunological

Phase 2

23

Immunologic Factors

Phase 2

24

Immune Checkpoint Inhibitors

Phase 2

25

Immunosuppressive Agents

Phase 2

26

Alkylating Agents

Phase 2

27

Antineoplastic Agents, Alkylating

Phase 2

28

Hypoglycemic Agents

Phase 2

29

Avelumab

Approved, Investigational

Phase 1

1537032-82-8

30

Poly I-C

Phase 1

Interventional clinical trials:

(show all 26)

#	Name	Status	NCT ID	Phase	Drugs
1	Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma	Recruiting	NCT05218499	Phase 2, Phase 3	BI 907828;Doxorubicin
2	SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma	Recruiting	NCT04967521	Phase 3	Abemaciclib;Placebo
3	A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)	Active, not recruiting	NCT02606461	Phase 2, Phase 3	Selinexor;Placebo
4	A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma	Active, not recruiting	NCT04979442	Phase 3	RAIN-32;Trabectedin
5	A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma	Unknown status	NCT02571829	Phase 2	ribociclib
6	A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma	Unknown status	NCT03096912	Phase 2	Ribociclib
7	Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	Unknown status	NCT03651375	Phase 2	Sequential chemotherapy - 3 courses of AI
8	Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	Completed	NCT01913652	Phase 2	Cabazitaxel
9	A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma	Completed	NCT02247544	Phase 2	Trabectedin
10	A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes	Recruiting	NCT04668300	Phase 2
11	A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma	Recruiting	NCT04438824	Phase 2	INCMGA00012;Palbociclib
12	A Phase II Study, With a Safety lead-in, to Evaluate ATX-101, a Peptide Drug Targeting PCNA, in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma	Recruiting	NCT05116683	Phase 2	ATX-101
13	Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma	Active, not recruiting	NCT03307616	Phase 2
14	Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma	Active, not recruiting	NCT02500797	Phase 2
15	Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)	Active, not recruiting	NCT03114527	Phase 2	Ribociclib;Everolimus
16	Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma	Active, not recruiting	NCT02846987	Phase 2	Abemaciclib
17	Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas	Active, not recruiting	NCT03989596	Phase 2
18	A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated Liposarcoma	Not yet recruiting	NCT05496569	Phase 2	TQB3616 capsule;TQB3616 placebo
19	A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas	Not yet recruiting	NCT05580588	Phase 2	SPH4336
20	A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)	Not yet recruiting	NCT04794127	Phase 2	Trabectedin;Pioglitazone Oral Product
21	Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial	Terminated	NCT01876043	Phase 2	plitidepsin
22	A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma	Withdrawn	NCT00969917	Phase 2	IPI-504
23	A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors	Recruiting	NCT03604783	Phase 1	TP-1287
24	A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma	Active, not recruiting	NCT04242238	Phase 1	DCC-3014;Avelumab
25	A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma	Active, not recruiting	NCT04420975	Phase 1
26	Correlation of DDLS Grading to OCT, HRT, and HVF	Completed	NCT00430287

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Sources

Genetic Tests for Dedifferentiated Liposarcoma

Sources

Anatomical Context for Dedifferentiated Liposarcoma

Organs/tissues related to Dedifferentiated Liposarcoma:

MalaCards : Lymph Node, Bone, Colon, Breast, Lung, Retina, Salivary Gland

Sources

Publications for Dedifferentiated Liposarcoma

Articles related to Dedifferentiated Liposarcoma:

(show top 50) (show all 969)

#	Title	Authors	PMID	Year
1	Well-differentiated and dedifferentiated liposarcomas. ⁵³ ⁶²	Coindre JM...Aurias A	19688222	2010
2	Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. ⁵³ ⁶²	Aleixo PB...Oliveira AM	19946100	2009
3	SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. ⁵³ ⁶²	Bouron-Dal Soglio D...Fournet JC	19454362	2009
4	Other targetable sarcomas. ⁵³ ⁶²	Pires de Camargo V...Thomas DM	19664496	2009
5	Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. ⁵³ ⁶²	de Vreeze RS...van Coevorden F	18820664	2009
6	Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. ⁵³ ⁶²	Weaver J...Rubin BP	18836421	2009
7	Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. ⁵³ ⁶²	Weaver J...Skacel M	18500263	2008
8	Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. ⁵³ ⁶²	Horvai AE...O'Donnell RJ	18204431	2008
9	Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. ⁵³ ⁶²	Singer S...Antonescu CR	17638873	2007
10	alpha-fetoprotein expression in a dedifferentiated liposarcoma. ⁵³ ⁶²	Bosco M...Pacchioni D	16489442	2006
11	[Extragastrointestinal stromal tumors: a report of 4 cases]. ⁵³ ⁶²	Ferchichi L...Baltagi Ben Jilani S	16472759	2006
12	Alterations of the RB1 gene in dedifferentiated liposarcoma. ⁵³ ⁶²	Takahira T...Tsuneyoshi M	15933756	2005
13	MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. ⁵³ ⁶²	Binh MB...Coindre JM	16160477	2005
14	Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. ⁵³ ⁶²	Coindre JM...Aurias A	12640106	2003
15	Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas. ⁵³ ⁶²	Schneider-Stock R...Roessner A	12210086	2002
16	Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. ⁵³ ⁶²	Ylagan LR...Bhalla S	11480734	2001
17	Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. ⁵³ ⁶²	Adachi T...Tsuneyoshi M	11484509	2001
18	Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. ⁵³ ⁶²	Boltze C...Roessner A	11518050	2001
19	Fibrohistiocytic differentiation in subcutaneous fatty tumors. Study of spindle cell, pleomorphic, myxoid, and atypical lipoma and dedifferentiated liposarcoma cases composed in part of CD34+ fibroblasts and FXIIIa+ histiocytes. ⁵³ ⁶²	Silverman JS...Tamsen A	9331894	1997
20	Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. ⁵³ ⁶²	Dei Tos AP...Fletcher CD	9071997	1997
21	Extending depolarized DLS measurements to turbid samples. ⁶²	Pal A...Schurtenberger P	35839555	2022
22	Assessment of optic disk by disk damage likelihood scale staging using slit-lamp biomicroscopy and optical coherence tomography in diagnosing primary open-angle glaucoma. ⁶²	Singh K...Pandey S	36453304	2022
23	Atypical spindle cell/pleomorphic lipomatous tumor with a sarcomatous component showing high mitotic activity and Ki-67 labeling index: report of a unique case mimicking dedifferentiated liposarcoma. ⁶²	Sugita S...Hasegawa T	35779129	2022
24	Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma. ⁶²	Jagosky MH...Kim ES	36464833	2022
25	Dedifferentiated liposarcoma in the abdominal cavity: a case report. ⁶²	Kuroda M...Nakagawa H	36315383	2022
26	Resection of the mediastinal dedifferentiated liposarcoma with trachea compression via the Masaoka approach. ⁶²	Wu CW...How CH	35739027	2022
27	Giant retroperitoneal dedifferentiated liposarcoma mimicking ovarian cancer: A case report. ⁶²	Tani A...Mori T	36299399	2022
28	Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma. ⁶²	Masaki N...Hoffman RM	36309387	2022
29	MRI findings to differentiate musculoskeletal dedifferentiated liposarcoma from atypical lipomatous tumor. ⁶²	Kawaguchi M...Matsuo M	36350422	2022
30	Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma. ⁶²	Delisle M...Nessim C	36088426	2022
31	A Contemporary Clinicopathologic Analysis of Primary Sarcomas of the Perinephric Soft Tissue and Hilar Vessels Including a Subset Secondarily Involving the Kidney. ⁶²	Scheiderer AN...Osunkoya AO	36437683	2022
32	Transcriptome analysis identifies TODL as a novel lncRNA associated with proliferation, differentiation, and tumorigenesis in liposarcoma through FOXM1. ⁶²	Kanojia D...Garg M	36167276	2022
33	Is preoperative CT-guided biopsy a valuable tool in the diagnostic workup of patients with visceral and retroperitoneal sarcoma? ⁶²	Luca Alatzides G...Schaarschmidt B	35985092	2022
34	Liposarcoma With Hibernoma-like Histology: A Clinicopathologic Study of 16 Cases. ⁶²	Kojima N...Yoshida A	35475774	2022
35	Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. ⁶²	Wilcock DM...Sirohi D	35261272	2022
36	Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). ⁶²	Sanfilippo R...Kasper B	35980618	2022
37	A rare case of parapharyngeal dedifferentiated liposarcoma in a 12-year-old boy. ⁶²	Kuwae Y...Ohsawa M	36300908	2022
38	Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry. ⁶²	Vincenzi B...Casali PG	36196483	2022
39	Paratesticular Dedifferentiated Liposarcoma with Epithelioid Features: A Diagnostic Pitfall. ⁶²	Patton A...Fritchie KJ	36113458	2022
40	Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. ⁶²	Thirasastr P...Somaiah N	36151848	2022
41	Dedifferentiated liposarcoma found in ovary: A rare case report. ⁶²	Chen J...Xia Y	36123846	2022
42	Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG). ⁶²	Morii T...Morioka H	36088237	2022
43	Primary dedifferentiated liposarcoma of the breast: A case report. ⁶²	Shrestha S...Shakya P	36093467	2022
44	Surgery of intraabdominal giant dedifferentiated liposarcoma of ascending colon mesentery: A rare case report. ⁶²	Park N...Lim DR	35973321	2022
45	Hypopharyngeal dedifferentiated liposarcoma treated by endoscopic submucosal dissection. ⁶²	Kawasaki K...Torisu T	36068123	2022
46	[STAT6 positive dedifferentiated liposarcoma: a clinicopathological analysis of two cases]. ⁶²	Du YY...Chen FF	35922170	2022
47	[The special case-Dedifferentiated liposarcoma of the spermatic cord]. ⁶²	Canal C...Conti M	35960320	2022
48	Dedifferentiated liposarcoma of the gallbladder: A rare case report. ⁶²	Zou RQ...Li FY	36041902	2022
49	Primary dedifferentiated liposarcoma mimicking malignant gastric stromal tumor. ⁶²	Liu F...Lin YX	35963700	2022
50	First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. ⁶²	Stacchiotti S...Kasper B	35561319	2022

Sources

Genes for Dedifferentiated Liposarcoma

Genes related to Dedifferentiated Liposarcoma (3 elite genes):

(show all 47)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MDM2	MDM2 Proto-Oncogene	Protein Coding	52.77	Role in the phenotype ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15221942 18500263 9071997 (more) 18214854 17638873 19946100 12640106 18204431 17895748 16160477 11518050 19688222 18836421 19737942 19664496 16442827 15242313 16489442 11484509 18820664
2	CDK4	Cyclin Dependent Kinase 4	Protein Coding	51.53	Role in the phenotype ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15221942 18214854 19737942 (more) 19946100 12640106 18204431 18820664 16442827 19664496 19454362 16160477 17895748 16489442
3	HMGA2	High Mobility Group AT-Hook 2	Protein Coding	40.85	Role in the phenotype ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18214854 19737942
4	DES	Desmin	Protein Coding	16.34	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9331894 11480734 16472759
5	TP53	Tumor Protein P53	Protein Coding	13.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	CD34	CD34 Molecule	Protein Coding	13.44	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	12.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16472759
8	PPARG	Peroxisome Proliferator Activated Receptor Gamma	Protein Coding	11.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	RB1	RB Transcriptional Corepressor 1	Protein Coding	11.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12210086 15933756
10	TODL	Transcript Overexpressed In Dedifferentiated Liposarcoma	RNA Gene	8.42	GeneCards inferred via : Gene name (show sections)
11	MIR193B	MicroRNA 193b	RNA Gene	7.66	DISEASES inferred ¹⁴ ¹⁴
12	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	7.4	GeneCards inferred via : Publications (show sections)
13	SERPINA3	Serpin Family A Member 3	Protein Coding	7.13	DISEASES inferred ¹⁴ ¹⁴
14	SS18	SS18 Subunit Of BAF Chromatin Remodeling Complex	Protein Coding	7.06	DISEASES inferred ¹⁴
15	F13A1	Coagulation Factor XIII A Chain	Protein Coding	7.06	GeneCards inferred via : Publications (show sections)
16	S100B	S100 Calcium Binding Protein B	Protein Coding	7.06	GeneCards inferred via : Publications (show sections)
17	EWSR1	EWS RNA Binding Protein 1	Protein Coding	6.93	DISEASES inferred ¹⁴
18	SSX2	SSX Family Member 2	Protein Coding	6.81	DISEASES inferred ¹⁴
19	MIR199A1	MicroRNA 199a-1	RNA Gene	6.79	DISEASES inferred ¹⁴ ¹⁴
20	DDIT3	DNA Damage Inducible Transcript 3	Protein Coding	6.72	DISEASES inferred ¹⁴
21	FUS	FUS RNA Binding Protein	Protein Coding	6.66	DISEASES inferred ¹⁴
22	NAB2	NGFI-A Binding Protein 2	Protein Coding	6.65	DISEASES inferred ¹⁴
23	NEBL	Nebulette	Protein Coding	6.56	DISEASES inferred ¹⁴ ¹⁴
24	SSX1	SSX Family Member 1	Protein Coding	6.47	DISEASES inferred ¹⁴
25	STAT6	Signal Transducer And Activator Of Transcription 6	Protein Coding	6.41	DISEASES inferred ¹⁴
26	TSPAN31	Tetraspanin 31	Protein Coding	6.36	DISEASES inferred ¹⁴
27	CLEC18C	C-Type Lectin Domain Family 18 Member C	Protein Coding	6.35	DISEASES inferred ¹⁴
28	CALD1	Caldesmon 1	Protein Coding	6.33	DISEASES inferred ¹⁴
29	CLEC18A	C-Type Lectin Domain Family 18 Member A	Protein Coding	6.32	DISEASES inferred ¹⁴
30	FRS2	Fibroblast Growth Factor Receptor Substrate 2	Protein Coding	6.3	DISEASES inferred ¹⁴
31	YEATS4	YEATS Domain Containing 4	Protein Coding	6.27	DISEASES inferred ¹⁴
32	ANO1	Anoctamin 1	Protein Coding	6.04	DISEASES inferred ¹⁴
33	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	5.95	DISEASES inferred ¹⁴
34	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	5.92	DISEASES inferred ¹⁴
35	MYOG	Myogenin	Protein Coding	5.92	DISEASES inferred ¹⁴
36	HEATR3	HEAT Repeat Containing 3	Protein Coding	5.81	DISEASES inferred ¹⁴
37	SMARCB1	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1	Protein Coding	5.8	DISEASES inferred ¹⁴
38	NF1	Neurofibromin 1	Protein Coding	5.68	DISEASES inferred ¹⁴
39	TLE1	TLE Family Member 1, Transcriptional Corepressor	Protein Coding	5.67	DISEASES inferred ¹⁴
40	VGLL3	Vestigial Like Family Member 3	Protein Coding	5.63	DISEASES inferred ¹⁴
41	ATRX	ATRX Chromatin Remodeler	Protein Coding	5.61	DISEASES inferred ¹⁴
42	CD274	CD274 Molecule	Protein Coding	5.57	DISEASES inferred ¹⁴
43	CTAG1B	Cancer/Testis Antigen 1B	Protein Coding	5.53	DISEASES inferred ¹⁴
44	PAX3	Paired Box 3	Protein Coding	5.52	DISEASES inferred ¹⁴
45	CTAG1A	Cancer/Testis Antigen 1A	Protein Coding	5.49	DISEASES inferred ¹⁴
46	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	5.41	DISEASES inferred ¹⁴
47	CDK6	Cyclin Dependent Kinase 6	Protein Coding	5.41	DISEASES inferred ¹⁴

Sources

Variations for Dedifferentiated Liposarcoma

Sources

Expression for Dedifferentiated Liposarcoma

Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.

Sources

Pathways for Dedifferentiated Liposarcoma

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Cellular Senescence ⁶⁶ Show member pathways Oxidative Stress Induced Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	12.61	CDK4 HMGA2 MDM2 RB1 TP53
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.58	TP53 RB1 MDM2 KIT CDK4
3	Malignant pleural mesothelioma ⁷⁴	12.41	TP53 MDM2 KIT DDIT3 CDK4 ACTC1
4	DNA Damage ³	12.4	TP53 RB1 MDM2 CDK4
5	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.31	TP53 RB1 MDM2 KIT CDK4
6	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.11	TP53 RB1 MDM2 CDK4
7	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.1	TP53 RB1 MDM2 CDK4
8	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.07	TP53 RB1 MDM2 CDK4
9	Integrated breast cancer pathway ⁷⁴	11.99	CDK4 MDM2 RB1 TP53
10	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	11.95	TP53 RB1 MDM2 CDK4
11	Small cell lung cancer ⁷⁴	11.78	TP53 RB1 CDK4
12	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.74	PPARG KIT DES CD34
13	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.7	TP53 PPARG MDM2
14	Overlap between signal transduction pathways contributing to LMNA laminopathies ⁷⁴ Show member pathways Influence of laminopathies on Wnt signaling ⁷⁴	11.67	RB1 PPARG HMGA2 CDK4
15	Head and neck squamous cell carcinoma ⁷⁴	11.64	TP53 RB1 CDK4
16	Retinoblastoma gene in cancer ⁷⁴	11.6	CDK4 MDM2 RB1 TP53
17	Prader-Willi and Angelman syndrome ⁷⁴	11.54	TP53 RB1 CDK4
18	ATF-2 transcription factor network ⁶¹	11.5	RB1 DDIT3 CDK4
19	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.34	TP53 MDM2 CDK4
20	Regulation of retinoblastoma protein ⁶¹	11.31	RB1 PPARG MDM2 CDK4
21	Bladder cancer ⁷⁴	11.06	TP53 RB1 MDM2 CDK4
22	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁴	10.95	TP53 RB1 MDM2
23	Integrated cancer pathway ⁷⁴	10.84	TP53 RB1 MDM2 CDK4
24	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity ⁷⁴	10.77	RB1 CDK4
25	Glycolysis in senescence ⁷⁴	10.49	TP53 RB1
26	Oncogene Induced Senescence ⁶⁶	10.44	TP53 RB1 MDM2 CDK4

Sources

GO Terms for Dedifferentiated Liposarcoma

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10	TP53 PPARG KIT HMGA2 CD34 ACTC1
2	negative regulation of gene expression	GO:0010629	9.76	TP53 RB1 PPARG MIR199A1 CD34
3	regulation of cell cycle	GO:0051726	9.65	TP53 RB1 MDM2 DDIT3 CDK4
4	cellular response to actinomycin D	GO:0072717	8.92	TP53 MDM2

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	disordered domain specific binding	GO:0097718	9.43	TP53 RB1 MDM2
2	RNA polymerase II-specific DNA-binding transcription factor binding	GO:0061629	9.32	TP53 RB1 HMGA2 DDIT3 CD34

Sources

Sources for Dedifferentiated Liposarcoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

DDLS MCID: DDF001 MIFTS: 45	Dedifferentiated Liposarcoma (DDLS) Categories: Cancer diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Dedifferentiated Liposarcoma (DDLS)

Aliases & Classifications for Dedifferentiated Liposarcoma

MalaCards integrated aliases for Dedifferentiated Liposarcoma:

Characteristics:

Prevelance:

Age Of Onset:

Classifications:

External Ids:

Summaries for Dedifferentiated Liposarcoma

Related Diseases for Dedifferentiated Liposarcoma

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

GenomeRNAi Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

Drugs & Therapeutics for Dedifferentiated Liposarcoma

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Dedifferentiated Liposarcoma

Anatomical Context for Dedifferentiated Liposarcoma

Organs/tissues related to Dedifferentiated Liposarcoma:

Publications for Dedifferentiated Liposarcoma

Articles related to Dedifferentiated Liposarcoma:

Genes for Dedifferentiated Liposarcoma

Genes related to Dedifferentiated Liposarcoma (3 elite genes):

Variations for Dedifferentiated Liposarcoma

Expression for Dedifferentiated Liposarcoma

Pathways for Dedifferentiated Liposarcoma

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

GO Terms for Dedifferentiated Liposarcoma

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

Sources for Dedifferentiated Liposarcoma